<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00000350</url>
  </required_header>
  <id_info>
    <org_study_id>NIDA-3-0010-15</org_study_id>
    <secondary_id>Y01-3-0010-15</secondary_id>
    <nct_id>NCT00000350</nct_id>
  </id_info>
  <brief_title>Effects of Stimulant Dependence on Human Striatal Dopamine System - 15</brief_title>
  <official_title>Effects of Stimulant Dependence on Human Striatal Dopamine System</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Institute on Drug Abuse (NIDA)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Institute on Drug Abuse (NIDA)</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether DAT availability, assessed by WIN binding,&#xD;
      in the striatum is altered in cocaine or methamphetamine dependence. To determine whether DA&#xD;
      synthesis capacity, assessed by FDOPA uptake, in the striatum is altered in Coc or Meth&#xD;
      dependence. To determine whether the PET tracers, WIN or FDOPA, will differentiate Meth&#xD;
      induced alterations from those induced by Coc use. To determine whether the PET&#xD;
      characterization of striatal alterations observed at 3-5 days since last drug use persists at&#xD;
      least 3 months after last drug use.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      4-5 Day inpatient study. Participant will have scanned pictures (MRI &amp; PET scans) taken of&#xD;
      their brain after being injected with a small amount of WIN, a radioactive substance.&#xD;
      Participants give daily urine samples and fill out health related questionnaires. It is&#xD;
      important to determine whether the alterations characterized within one week of last drug use&#xD;
      persist over a longer time period. Based on results of the studies from aims 1 &amp; 2, we will&#xD;
      decide which of the 2 probes, WIN or FDOPA-PET is the more sensitive index of&#xD;
      stimulant-dependency-induced changes.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>March 1999</start_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <enrollment>0</enrollment>
  <condition>Amphetamine-Related Disorders</condition>
  <condition>Tobacco Use Disorder</condition>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>radioactive substance</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        M/F, ages 21-50. Meet DSM-IV criteria for methamphetamine and nicotine dependence. Agree to&#xD;
        conditions of the study and sign informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Psychiatric disorder that requires medication therapy. History of seizures. Pregnant and/or&#xD;
        nursing women. Dependence on ETOH or benzodiazepines or other sedative/hypnotics. Acute&#xD;
        hepatitis. Other medical conditions that deem participation to be unsafe.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Walter Ling, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Friends Research Institute, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Friends Research Institute</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90025</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 1999</verification_date>
  <study_first_submitted>September 20, 1999</study_first_submitted>
  <study_first_submitted_qc>September 20, 1999</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 21, 1999</study_first_posted>
  <last_update_submitted>January 10, 2017</last_update_submitted>
  <last_update_submitted_qc>January 10, 2017</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 11, 2017</last_update_posted>
  <keyword>amphetamine dependence</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Disease</mesh_term>
    <mesh_term>Tobacco Use Disorder</mesh_term>
    <mesh_term>Amphetamine-Related Disorders</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

